The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 20, 2015

Filed:

Sep. 14, 2012
Applicants:

Eva Kontsekovà, Sencec, SK;

Peter Filipcik, Bratislava, SK;

Inventors:

Eva Kontsekovà, Sencec, SK;

Peter Filipcik, Bratislava, SK;

Assignee:

Axon Neuroscience SE, Bratislava, SK;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01K 67/027 (2006.01); A01K 67/033 (2006.01); C07K 14/47 (2006.01); C12N 15/85 (2006.01); G01N 33/50 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A01K 67/0278 (2013.01); C07K 14/4711 (2013.01); C12N 15/8509 (2013.01); G01N 33/5088 (2013.01); G01N 33/6896 (2013.01); A01K 2207/15 (2013.01); A01K 2217/00 (2013.01); A01K 2217/05 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0312 (2013.01); A61K 39/00 (2013.01); G01N 2800/2821 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present invention provides transgenic non-human animals and non-human mammalian somatic and germ cells harboring a human DNA sequence encoding Alzheimer's Disease (AD) derived tau protein, capable of inducing AD pathology in transgenic animals. Alzheimer's tau protein is expressed on specific genetic backgrounds allowing also simulation of different human diseases including hypertension, diabetes, hyper-cholesterolemia, which are associated with neurodegeneration and are considerable risk factors for AD development. Transgenic animals and cells of the invention exhibit neurofibrillary pathology and may serve as in vivo and in vitro assay systems for screening and developing therapeutic and preventive substances and also diagnostic markers and probes for tauopathies and AD. Furthermore these transgenic animals and cell lines derived thereof provide an in vivo and in vitro assay system for neurodegenerative disorders preferably tauopathies and AD result from combinations with other disease as hypertension and others representing risk factors associated with the process of neurodegeneration.


Find Patent Forward Citations

Loading…